Flerie AB (OSTO:FLERIE) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:FLERIE Flerie AB OSTO:FLERIE
26 GF Score
Price kr20.50
! 2 Warning Signs
View Full Analysis

What is Flerie AB FFO?

FFO (Funds from operations) only applies to REITs.

OSTO:FLERIE
26GF Score
Flerie AB OSTO:FLERIE
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Flerie AB Business Description

Other Exchanges 1NP1:Germany
Address Skeppsbron 16, Stockholm, SWE, 111 30
Flerie AB is a pharmaceutical company focusing on immunological diseases with great medical needs for new treatment options. The portfolio of the company includes Immuno-Oncology, metabolic diseases, and biologics development and manufacturing organizations. It operates in two segments The Product Development segment, and The Commercial Growth segment. The Product Development segment consists of early and mid-stage biotech and pharma companies advancing their products and technologies toward clinical proofof-concept and marketing approvals. The Commercial Growth segment consists of companies already selling products or services, showcasing their ability to generate increasing revenues ahead of reaching sustainable profitability.
26GF Score

Get the complete analysis for OSTO:FLERIE

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr20.50
Price